A study from Japan showed that the triple-negative breast cancer had the worst outcomes in patients aged ≤40 years, while comparable outcomes were found among the luminal A, luminal B, and HER2 overexpression subtypes [35]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.